Novartis’ partners at Conatus have another NASH setback to confess today

Eight months after Conatus’ execs tried unsuccessfully to sell a silver-lining playbook story to investors about the failure of a Phase IIb trial for their drug emricasan in fibrosis and cirrhosis, they’re back with another failed Phase IIb — and once again they’ve set out to try and sell it as a win.